36.52
전일 마감가:
$37.12
열려 있는:
$37.49
하루 거래량:
2.65M
Relative Volume:
2.75
시가총액:
$3.55B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-5.6445
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
-1.67%
1개월 성능:
+4.10%
6개월 성능:
-15.89%
1년 성능:
-11.83%
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RARE
Ultragenyx Pharmaceutical Inc
|
36.52 | 3.55B | 522.75M | -558.99M | -439.53M | -6.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-28 | 개시 | William Blair | Outperform |
2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2023-06-14 | 재개 | Credit Suisse | Outperform |
2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
2023-01-18 | 재개 | Canaccord Genuity | Buy |
2022-12-30 | 재개 | H.C. Wainwright | Buy |
2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-09-30 | 개시 | H.C. Wainwright | Buy |
2021-08-19 | 개시 | UBS | Sell |
2021-07-15 | 개시 | Guggenheim | Neutral |
2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
2021-06-04 | 재개 | Robert W. Baird | Neutral |
2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
2021-04-26 | 재개 | Credit Suisse | Neutral |
2021-03-02 | 재개 | Stifel | Buy |
2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
2020-11-24 | 재개 | Evercore ISI | In-line |
2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
2019-08-02 | 재개 | Wedbush | Outperform |
2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-02-22 | 재개 | Raymond James | Outperform |
2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
2018-05-10 | 개시 | Goldman | Neutral |
2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
2018-03-22 | 재개 | Piper Jaffray | Overweight |
2018-02-21 | 재확인 | Stifel | Buy |
2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
2018-01-18 | 개시 | Credit Suisse | Outperform |
2017-12-05 | 재확인 | Barclays | Equal Weight |
2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Exploring the Road Ahead: X-linked Hypophosphatemia Market - openPR.com
(RARE) Long Term Investment Analysis - news.stocktradersdaily.com
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com Canada
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia
FDA approves Ultragenyx's Mepsevii in mucopolysaccharidosis type VII enzyme disorder - FirstWord Pharma
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Ultragenyx (RARE) Q1 2025 Performance Shows Resilience - GuruFocus
Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com
How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com
Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq
Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN
William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus
William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com
William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com
Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus
Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):